Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer

OBJECTIVES: PARP inhibitors (PARPi) are a novel class of drugs with activity in patients with acquired or germline homologous recombination (HR) deficiency-associated high-grade serous ovarian cancer (HGSOC). We hypothesized that measuring γH2AX as an indicator of DNA double-strand breaks (DSB), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Min, Gordon, Nicolas, Trepel, Jane B, Lee, Min-Jung, Yu, Minshu, Kohn, Elise C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508767/
https://www.ncbi.nlm.nih.gov/pubmed/26198537
http://dx.doi.org/10.1186/s12967-015-0604-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508767/
https://www.ncbi.nlm.nih.gov/pubmed/26198537
http://dx.doi.org/10.1186/s12967-015-0604-z

Ejemplares similares